-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Breast cancer has become the number one cancer in the world and the number one cancer among women in my country.
However, the listing of UTI Delong (UTI Di ® ) changed this situation.
® ®
Group photo of guests at the launching ceremony of UTI Delong Charity Aid Conference and New Drug Launch Conference
Group photo of guests at the launching ceremony of UTI Delong Charity Aid Conference and New Drug Launch ConferenceSun Yan, Academician of the Chinese Academy of Engineering and Honorary Director of the National Center for New Drugs (Anti-tumor) Clinical Research, Chen Kaixian, Academician of the Chinese Academy of Sciences and Deputy Chief Technology Officer of the National Major Science and Technology Project "Major New Drug Creation", and Deng Zixin, Academician of the Chinese Academy of Sciences and Director of the State Key Laboratory of Microbial Metabolism, Professor Xu Binghe, Tumor Hospital of Chinese Academy of Medical Sciences, Yu Hui, Deputy Secretary of the Party Working Committee and Director of the Management Committee of Chengdu High-tech Zone, Zhang Guang, Deputy Director of the Management Committee of Beijing Economic and Technological Development Zone, Guo Huiling, Secretary General of Beijing Huakang Charity Foundation, Beijing Hua Dr.
Professor Xu Binghe from the Cancer Hospital of the Chinese Academy of Medical Sciences said that although this is the era of targeted and immunotherapy, chemotherapeutics are still indispensable.
In order to quickly benefit more cancer patients with the original blockbuster and innovative drugs developed locally, Uti Delong and Beijing Huakang Public Welfare Foundation jointly launched the "Youxiang Newborn-Breast Cancer Patient Assistance Project" while on the market.
Patients using the first application of the 4 courses at their own expense (at least 20 bottles) for excellent emperor ® after drugs, if the assessment by project doctors to continue to use excellent for Emperor ® side effects further treatment, and all tolerated, up to a maximum obtainable Aid medicines for more than 4 courses (the amount of assistance does not exceed the amount at your own expense).
® ® ®
In the future, UTI Delong will also promote the exploration of different channels in the domestic medical insurance, commercial insurance, and multi-party payment modes, and expand the international market, expand the availability of new drugs, and give play to the value of local research and development results.
